The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction

Thrombosis and Haemostasis

Volumn 105, Issue 1, 2011, Pages 59-65

  Caram, Camila ^a   De Souza, Roberta Grazielle ^b   De Sousa, Júlio Carepa ^c   Pereira, Tatiana Araújo ^d   Cerqueira, Ana Maria Do Amaral ^e   Van Der Bom, Johanna G ^f   Rezende, Suely Meireles ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Prefeitura de Pará de Minas ^*  (Brazil)

^c Target MandE Consultoria   (Brazil)

^d Sulamérica   (Brazil)

^e FUNDAÇÃO HEMOMINAS   (Brazil)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alloantibody; Factor VIII; Haemophilia; Inhibitor; Natural history

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTIBODY TITER; ARTICLE; CRYOPRECIPITATE; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; HEMOPHILIA; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INFANT; ISOANTIBODIES; LONGITUDINAL STUDIES; OBSERVATION; RETROSPECTIVE STUDIES; TIME; TITRIMETRY; YOUNG ADULT;

EID: 78651076712     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-04-0231     Document Type: Article

References (28)

1. Ehrenforth S KW, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
2. Kempton CL SJ, Abshire TC. Incidence of inhibitors in a cohort of 838 males with haemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4: 2576-2581.
3. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-435.
4. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-57.
5. Mariani G, Kroner B. Immune tolerance in haemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86: 1186-1193.
6. Rezende SM, Pinheiro K, Caram C, et al. Registry of inherited coagulopathies in Brazil: first report. Haemophilia 2009; 15: 142-149.
7. Astermark J, Oldenburg J, Carlson J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with haemophilia A. Blood 2006; 108: 3739-3745.
8. Astermark J, Oldenburg J, Pavlova A, et al. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with haemophilia A. Blood 2006; 107: 3167-3172.
9. Gouw SC, van der Bom JG, Auerswald G, et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe haemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-4697.
10. Gouw SC, van der Bom JG, van den Berg MH. Treatment-related risk factors of inhibitor development in previously untreated patients with haemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-4654.
11. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12 (Suppl 6): 15-22.
12. Astermark J WX, Oldenburg J, Berntorp E, et al. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe haemophilia A J Thromb Haemost 2007; 5: 263-265.
13. Lorenzo JI LA, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600-603.
14. Oldenburg J SJ, Brackmann HH, Muller-Reible C, et al. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41: 82-88.
15. van der Bom JG M-BE, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe haemophilia. Thromb Haemost 2003; 89: 475-479.
16. Gilbert C. White I, Frits Rosendaal, et al., on behalf of the Factor VIII and Factor IX Subcommittee. Scientific and Standardization Committee Communication: Definitions in Haemophilia. ISTH Website 29 November, 2000; Available at: http://www.isth.org.
17. Kasper CK, Aledort L, Aronson D, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
18. McMillan CW, Shapiro SS, Whitehurst D, et al. The natural history of factor VIII: C inhibitors in patients with haemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII: C inhibitors. Blood 1988; 71: 344-348.
19. Yee TT, Pasi KJ, Lilley PA, et al. Factor VIII inhibitors in haemophiliacs: a singlecentre experience over 34 years, 1964-97. Br J Haematol 1999; 104: 909-914.
20. Rasi V IE. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76: 369-371.
21. Schwarzinger I PI, Korninger C, Haschke F, et al. Incidence of inhibitors in patients with severe and moderate haemophilia A treated with factor VIII concentrates Am J Hematol 1987; 24: 241-245.
22. Canada AoHCDo. Canadian Haemophilia Registry and Inherited Bleeding Disorders Registry. Available at http://www.fhs.mcmaster.ca/chr/data.html. Last update on May 13, 2010.
23. Services DoHah. Bleeding and Clotting Disorders Surveillance. Center for Diseases control. Available at http://www.cdc.gov/ncbddd/blooddisorders/udc/ index.html. Last update on May 1, 2010.
24. Lenk H. The German Registry of immune tolerance treatment in haemophilia - 1999 update. Haematologica 2000 Oct; 85 (10 Suppl): 45-47.
25. Kroner B. Comparison of the International Immune Tolerance Registry and the North American Immune Tolerance Registry. Vox Sang 1999; 77: 33-37. (Pubitemid 29469254)
26. Kasper CK. Effect of prothrombin complex concentrates on factor VIII inhibitor levels. Blood 1979; 54: 1358-1368.
27. Strauss HS, Merler E. Characterization and properties of an inhibitor of factor 8 in the plasma of patients with haemophilia A following repeated transfusions. Blood 1967; 30: 137-150.
28. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-251.